These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36707893)

  • 1. Cannabis-opioid interaction in the treatment of fibromyalgia pain: an open-label, proof of concept study with randomization between treatment groups: cannabis, oxycodone or cannabis/oxycodone combination-the SPIRAL study.
    van Dam CJ; van Velzen M; Kramers C; Schellekens A; Olofsen E; Niesters M; Dahan A
    Trials; 2023 Jan; 24(1):64. PubMed ID: 36707893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxycodone for neuropathic pain and fibromyalgia in adults.
    Gaskell H; Moore RA; Derry S; Stannard C
    Cochrane Database Syst Rev; 2014 Jun; (6):CD010692. PubMed ID: 24956205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain.
    Arora S; Setnik B; Michael D; Hudson JD; Clemmer R; Meisner P; Pixton GC; Goli V; Sommerville KW
    J Opioid Manag; 2014; 10(6):423-36. PubMed ID: 25531960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic study on the impact of side effects in patients taking oxycodone controlled-release for noncancer pain.
    Anastassopoulos KP; Chow W; Tapia CI; Baik R; Ackerman SJ; Biondi D; Kim MS
    J Manag Care Pharm; 2012 Oct; 18(8):615-26. PubMed ID: 23127149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxycodone for cancer-related pain.
    Schmidt-Hansen M; Bennett MI; Arnold S; Bromham N; Hilgart JS
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD003870. PubMed ID: 28829910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
    Hale M; Tudor IC; Khanna S; Thipphawong J
    Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combatting pain after orthopedic/trauma surgery- perioperative oral extended-release tapentadol vs. extended-release oxycodone/naloxone.
    Haeseler G; Schaefers D; Prison N; Ahrens J; Liu X; Karch A
    BMC Anesthesiol; 2017 Jul; 17(1):91. PubMed ID: 28693439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxycodone for neuropathic pain in adults.
    Gaskell H; Derry S; Stannard C; Moore RA
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD010692. PubMed ID: 27465317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged-Release (PR) Oxycodone/Naloxone Improves Bowel Function Compared with Oxycodone PR and Provides Effective Analgesia in Chinese Patients with Non-malignant Pain: A Randomized, Double-Blind Trial.
    Leng X; Zhang F; Yao S; Weng X; Lu K; Chen G; Huang M; Huang Y; Zeng X; Hopp M; Lu G
    Adv Ther; 2020 Mar; 37(3):1188-1202. PubMed ID: 32020565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioid-Induced Constipation Relief From Fixed-Ratio Combination Prolonged-Release Oxycodone/Naloxone Compared With Oxycodone and Morphine for Chronic Nonmalignant Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Huang L; Zhou JG; Zhang Y; Wang F; Wang Y; Liu DH; Li XJ; Lv SP; Jin SH; Bai YJ; Ma H
    J Pain Symptom Manage; 2017 Nov; 54(5):737-748.e3. PubMed ID: 28736104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxycodone for cancer-related pain.
    Schmidt-Hansen M; Bennett MI; Arnold S; Bromham N; Hilgart JS
    Cochrane Database Syst Rev; 2015 Feb; (2):CD003870. PubMed ID: 25723351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: pooled analysis of randomized studies.
    Merchant S; Provenzano D; Mody S; Ho KF; Etropolski M
    J Opioid Manag; 2013; 9(1):51-61. PubMed ID: 23709304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analgesic Efficacy and Safety of Prolonged-Release Oxycodone/Naloxone in Korean Patients with Chronic Pain from Spinal Disorders.
    Hwang CJ; Chung SS; Lee KY; Lee JH; Moon SH; Kim JH; Cho KJ; Ahn JS; Kim DS; Park YS; Park HJ
    Clin Orthop Surg; 2018 Mar; 10(1):33-40. PubMed ID: 29564045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of oxycodone-naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study.
    Guerriero F; Roberto A; Greco MT; Sgarlata C; Rollone M; Corli O
    Drug Des Devel Ther; 2016; 10():1515-23. PubMed ID: 27143857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain.
    Simpson K; Leyendecker P; Hopp M; Müller-Lissner S; Löwenstein O; De Andrés J; Troy Ferrarons J; Bosse B; Krain B; Nichols T; Kremers W; Reimer K
    Curr Med Res Opin; 2008 Dec; 24(12):3503-12. PubMed ID: 19032132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
    Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
    Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes.
    Webster LR; Slevin KA; Narayana A; Earl CQ; Yang R
    Pain Med; 2013 Sep; 14(9):1332-45. PubMed ID: 23855816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study.
    Dupoiron D; Stachowiak A; Loewenstein O; Ellery A; Kremers W; Bosse B; Hopp M
    Eur J Pain; 2017 Oct; 21(9):1485-1494. PubMed ID: 28474460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability, Safety, and Effectiveness of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain: A Randomized Controlled Trial.
    Kopecky EA; Vaughn B; Lagasse S; O'Connor M
    Drugs Aging; 2017 Aug; 34(8):603-613. PubMed ID: 28600725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.